Concurrent Investment Advisors LLC Increases Stock Holdings in Novo Nordisk A/S $NVO

Concurrent Investment Advisors LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 84.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,685 shares of the company’s stock after buying an additional 45,955 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,123,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC increased its position in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at $25,000. Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter valued at $30,000. WealthCollab LLC increased its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares in the last quarter. Finally, American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage pediatric trial win — oral semaglutide met its main goal in 10–17 year olds with type 2 diabetes, supporting a planned U.S. launch and expanding addressable market for an oral GLP‑1 in youth. Novo Nordisk’s new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Market reaction to trial news — outlets report NVO shares rising after the pediatric oral semaglutide data, indicating investor enthusiasm for incremental product launches and revenue growth. Novo Nordisk Shares Rise After Positive Oral Semaglutide Trial In Children
• Positive Sentiment: Competitive edge in obesity market — early prescription data show Lilly’s new obesity treatment trailing Novo’s Wegovy, pressuring Lilly shares and reinforcing Novo’s market leadership in weight‑loss drugs. Eli Lilly slips as obesity scripts said to trail those for Novo’s Wegovy
• Positive Sentiment: Short interest fell sharply — short interest declined ~14.6% in April to ~17.0M shares (0.4% of float), lowering potential short‑squeeze risk and signaling reduced bearish positioning. (internal short‑interest data)
• Neutral Sentiment: Valuation/price discussion — analysts and commentators are parsing whether current pricing reflects recent share weakness and longer‑term growth prospects; this keeps the stock sensitive to further data and guidance. Is Novo Nordisk (NYSE:NVO) Pricing Reflect Its Recent Share Slump And Growth Outlook
• Negative Sentiment: Analyst target trimmed — Citigroup cut its price target (DKK 309 → DKK 275) while keeping a neutral rating, a reminder of lingering valuation concerns that could cap upside. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Recent short‑term pullbacks — coverage noted a recent session where NVO closed lower, highlighting that momentum can reverse on macro or sector weakness. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market

Novo Nordisk A/S Trading Up 0.1%

Novo Nordisk A/S stock opened at $41.19 on Monday. The stock has a market cap of $183.93 billion, a PE ratio of 11.87, a P/E/G ratio of 9.80 and a beta of 0.73. The stock has a 50-day moving average price of $39.13 and a 200 day moving average price of $47.65. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 50.43%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NVO. Citigroup began coverage on Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.